LXRX logo

Lexicon Pharmaceuticals (LXRX) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

07 April 2000

Indexes:

Not included

Description:

Lexicon Pharmaceuticals (LXRX) is a biopharmaceutical company focused on developing new medicines for serious diseases. They use advanced technology to discover and create treatments, particularly for conditions like diabetes and rare genetic disorders. Their goal is to improve patients' lives through innovative therapies.

Key Details

Price

$0.82

Annual Revenue

$1.20 M(+766.19% YoY)

Annual EPS

-$0.80(-29.03% YoY)

Annual ROE

-168.50%

Beta

1.85

Events Calendar

Earnings

Next earnings date:

May 02, 2025

Recent quarterly earnings:

Nov 12, 2024

Recent annual earnings:

Mar 02, 2023
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

May 21, 2015

Analyst ratings

Recent major analysts updates

25 Nov '24 Needham
Hold
22 Nov '24 Needham
Hold
13 Nov '24 Needham
Hold
13 Nov '24 HC Wainwright & Co.
Buy
05 Nov '24 HC Wainwright & Co.
Buy
01 Nov '24 Needham
Hold
01 Nov '24 HC Wainwright & Co.
Buy
30 Oct '24 Needham
Hold
30 Oct '24 HC Wainwright & Co.
Buy
23 Oct '24 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Lexicon Pharmaceuticals to Participate in December Investor Conferences
Lexicon Pharmaceuticals to Participate in December Investor Conferences
Lexicon Pharmaceuticals to Participate in December Investor Conferences
LXRX
globenewswire.com25 November 2024

THE WOODLANDS, Texas, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company management, including Mike Exton, Lexicon's chief executive officer and director, will present at two upcoming investor conferences in December.

Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA
Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA
Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA
LXRX
globenewswire.com22 November 2024

Implementing Strategic Restructuring to Eliminate Commercial Organization and Rationalize Operations Across All Functions

Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2024 Earnings Call Transcript
Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2024 Earnings Call Transcript
Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2024 Earnings Call Transcript
LXRX
seekingalpha.com12 November 2024

Start Time: 17:00 January 1, 0000 5:55 PM ET Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Q3 2024 Earnings Call November 12, 2024, 17:00 PM ET Company Participants Mike Exton - CEO and Director Tom Garner - SVP and Chief Commercial Officer Craig Granowitz - SVP and Chief Medical Officer Alan Main - EVP, Innovation and Chemical Sciences Lisa DeFrancesco - Head, IR and Corporate Strategy Conference Call Participants Andrew Tsai - Jeffries Joseph Stringer - Needham and Company Joe Pantginis - H.C. Wainwright Yigal Nochomovitz - Citigroup Roanna Ruiz - Leerink Partners Operator Good day, and welcome to the Lexicon Pharmaceuticals Third Quarter 2024 Results Conference Call.

Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Lags Revenue Estimates
Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Lags Revenue Estimates
Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Lags Revenue Estimates
LXRX
zacks.com12 November 2024

Lexicon Pharmaceuticals (LXRX) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.21 per share a year ago.

Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
LXRX
globenewswire.com12 November 2024

Announced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and Europe

Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease
Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease
Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease
LXRX
globenewswire.com31 October 2024

THE WOODLANDS, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the outcome of the U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting to review the company's New Drug Application (NDA) for Zynquista (sotagliflozin), an oral SGLT1/SGLT2 inhibitor, as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes (T1D) and chronic kidney disease (CKD). The Advisory Committee voted 11 to 3 that the benefits of Zynquista do not outweigh the risks in adults with T1D and CKD, as defined in the voting question as having estimated glomerular filtration rate (eGFR) > 45 to 60 mL/min/1.73 m2 and urine albumin-to-creatinine ratio (uACR) > 30mg/g.

FDA advisers vote against Lexicon Pharma's add-on drug for type 1 diabetes
FDA advisers vote against Lexicon Pharma's add-on drug for type 1 diabetes
FDA advisers vote against Lexicon Pharma's add-on drug for type 1 diabetes
LXRX
reuters.com31 October 2024

Independent advisers to the U.S. Food and Drug Administration on Thursday voted against recommending Lexicon Pharmaceuticals' add-on treatment to insulin therapy for managing blood glucose levels in adults with type 1 diabetes and chronic kidney disease.

Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer
Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer
Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer
LXRX
globenewswire.com16 September 2024

THE WOODLANDS, Texas, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeff Wade, president and chief operating officer, has decided to step down to pursue new opportunities outside of Lexicon, effective September 30, 2024. A search for a new chief financial officer is ongoing.

New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes
New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes
New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes
LXRX
globenewswire.com10 September 2024

Study results aligned with positive clinical trial outcomes for type 1 diabetes treatment with sotagliflozin

Lexicon (LXRX) Up as FDA Maintains Action Date for Zynquista
Lexicon (LXRX) Up as FDA Maintains Action Date for Zynquista
Lexicon (LXRX) Up as FDA Maintains Action Date for Zynquista
LXRX
zacks.com22 August 2024

The FDA plans to hold an Advisory Committee meeting to give a recommendation for Lexicon's (LXRX) Zynquista (sotagliflozin) on Oct 31, 2024. Stock up.

FAQ

  • What is the primary business of Lexicon Pharmaceuticals?
  • What is the ticker symbol for Lexicon Pharmaceuticals?
  • Does Lexicon Pharmaceuticals pay dividends?
  • What sector is Lexicon Pharmaceuticals in?
  • What industry is Lexicon Pharmaceuticals in?
  • What country is Lexicon Pharmaceuticals based in?
  • When did Lexicon Pharmaceuticals go public?
  • Is Lexicon Pharmaceuticals in the S&P 500?
  • Is Lexicon Pharmaceuticals in the NASDAQ 100?
  • Is Lexicon Pharmaceuticals in the Dow Jones?
  • When was Lexicon Pharmaceuticals's last earnings report?
  • When does Lexicon Pharmaceuticals report earnings?
  • Should I buy Lexicon Pharmaceuticals stock now?

What is the primary business of Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals (LXRX) is a biopharmaceutical company focused on developing new medicines for serious diseases. They use advanced technology to discover and create treatments, particularly for conditions like diabetes and rare genetic disorders. Their goal is to improve patients' lives through innovative therapies.

What is the ticker symbol for Lexicon Pharmaceuticals?

The ticker symbol for Lexicon Pharmaceuticals is NASDAQ:LXRX

Does Lexicon Pharmaceuticals pay dividends?

No, Lexicon Pharmaceuticals does not pay dividends

What sector is Lexicon Pharmaceuticals in?

Lexicon Pharmaceuticals is in the Healthcare sector

What industry is Lexicon Pharmaceuticals in?

Lexicon Pharmaceuticals is in the Biotechnology industry

What country is Lexicon Pharmaceuticals based in?

Lexicon Pharmaceuticals is headquartered in United States

When did Lexicon Pharmaceuticals go public?

Lexicon Pharmaceuticals's initial public offering (IPO) was on 07 April 2000

Is Lexicon Pharmaceuticals in the S&P 500?

No, Lexicon Pharmaceuticals is not included in the S&P 500 index

Is Lexicon Pharmaceuticals in the NASDAQ 100?

No, Lexicon Pharmaceuticals is not included in the NASDAQ 100 index

Is Lexicon Pharmaceuticals in the Dow Jones?

No, Lexicon Pharmaceuticals is not included in the Dow Jones index

When was Lexicon Pharmaceuticals's last earnings report?

Lexicon Pharmaceuticals's most recent earnings report was on 12 November 2024

When does Lexicon Pharmaceuticals report earnings?

The next expected earnings date for Lexicon Pharmaceuticals is 2 May 2025

Should I buy Lexicon Pharmaceuticals stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions